Gender, BMI impact bladder perforation during resection

Share this article:
Gender, BMI Impact Bladder Perforation During Resection
Gender, BMI Impact Bladder Perforation During Resection

(HealthDay News) -- For patients with bladder tumors, female gender, low body mass index, and tumor characteristics correlate with the risk of bladder perforation during transurethral resection, according to research published in the May issue of The Journal of Urology.

To investigate risk factors for bladder perforation, Kathleen Herkommer, M.D., from Technische Universität München in Munich, Germany, and colleagues retrospectively reviewed records from 1,284 patients who underwent transurethral resection of bladder tumors between 1986 and 2006.

The researchers found that 89.8 percent of the 49 bladder perforations were extraperitoneal. The risk of bladder perforation correlated significantly with gender (7.2 percent for female versus 2.6 percent for male; P < 0.001); body mass index (<25 kg/m², 5.5 percent; 25 to 30 kg/m², 3.4 percent; >30 kg/m², 0.6 percent; P = 0.016); and with more advanced tumor stage, greater infiltration depth, and higher resection weight. There was no association seen between bladder perforation and patient age, nicotine use, gross hematuria at diagnosis, transurethral catheterization, bladder stones, number of tumors, or tumor grade.

"Aside from tumor characteristics female gender and low body mass index were risk factors for inadvertent bladder perforation during transurethral resection of bladder tumors," the authors write.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Idelalisib approved by FDA for three types of blood cancer

Idelalisib approved by FDA for three types of ...

Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, but label warns drug may be toxic to the liver.

Physicians cautioned about counterfeit medical devices

Physicians cautioned about counterfeit medical devices

Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices.

Women undergoing morcellation have in 27 in 10k uterine cancer prevalence

Women undergoing morcellation have in 27 in 10k ...

For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age, according to a research letter published online.